The prospects for cisplatin and nab-paclitaxel combination therapy in patients with pre-treated triple-negative breast cancer. Description of the clinical case.
https://doi.org/10.21518/2079-701X-2018-10-49-55
Abstract
Molecular and biological features of triple negative breast cancer (TN BC) determine the limited possibilities of systemic therapy and, as a consequence, the more aggressive course of the disease. Taxanes are one of the most effective chemotherapies used in breast cancer therapy. The special form of paclitaxel nab-paclitaxel makes it possible to obtain an objective and a subjective effect, which is especially important in the pre-treated patients. In addition, the drug has a favourable safety profile and a well-controlled toxicity.
The article contains a review of the literature on the prospects for the use of nab-paclitaxel in breast cancer, especially in its triple negative version, and a description of the clinical case of therapy with a combination of cisplatin and nab-paclitaxel in a young patient with BRCA-1-associated TN breast cancer.
About the Authors
L. G. Zhukova
Blokhin Russian Medical Research Centre of Oncology of the Ministry of Health of Russia
Russian Federation
Russian Federation
K. S. Bardovskaya
Loginov Moscow Clinical Research Center of the Moscow Department of Health
Russian Federation
Russian Federation
E. V. Lubennikova
Blokhin Russian Medical Research Centre of Oncology of the Ministry of Health of Russia
Russian Federation
Russian Federation
I. R. Suslova
Oncology Centre No. 4 of the Moscow Department of Health
Russian Federation
Oncology Centre No. 4 of the Moscow Department of Health
Russian Federation
Oncology Centre No. 4 of the Moscow Department of Health
References
1. Kaprin AD, Starinsky VV, Petrova GV. Malignant neoplasms in Russia in 2016 (morbidity and mortality). Moscow: Herzen Medical Research Cancer Institute, a branch of National Medical Research Radiology Institute of the Ministry of Health of Russia. 2018. 250 p.
2. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature, 2000, 406: 747–52.
3. Metzger-Filho O, Tutt A, de Azambuja E et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol, 2012, 30: 1879–87.
4. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol, 2012, 23(Suppl. 6): vi7–vi12.
5. Alba E, Chacon JI, Lluch A, et al. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat, 2012, 136(2): 487–493.
6. Conlin AK, Seidman AD. Taxanes in breast cancer: an update. Curr Oncol Rep, 2007, 9: 22-30.
7. John TA, Vogel SM, Tiruppathi C, et al. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol, 2003, 284(1): L187-96.
8. Desai N. Nab technology: a drug delivery platform utilising endothelial gp60 receptor-based transport and tumour-derived SPARC for targeting. Drug Delivery Report 16th edition. 2007/2008: 37-41.
9. Schettini F, Giuliano M, et al. Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. Cancer Treat Rev, 2016 Nov, 50: 129-141.
10. Sen S, Kato S, Agarwal R, et al. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer, 2018, Apr 26.
11. FDA. ABRAXANE! for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). 2007. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2008/021660s013lbl.pdf.
12. Инструкция к медицинскому применению препарата Абраксан: ЛСР-009047/10-230817./ Patient Information Leaflet for Abraxan: LSR009047/10-230817.
13. Untch M, Jackisch C, Schneeweiss A, et al. Nabpaclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto–GBG 69): a randomised, phase 3 trial. Lancet Oncol, 2016, 17(Issue 3): 345-356.
14. Schneeweiss A. SABCS 2017.
15. Gianni L, Mansutti M, Anton A, et al. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. JAMA Oncol, 2018 Mar 1, 4(3): 302-308.
16. Ueno NT, Mamounas EP. Neoadjuvant nabpaclitaxel in the treatment of breast cancer. Breast Cancer Research and Treatment, 2016, 156: 427-440.
17. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of Neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol, 2011, 28(7): 1145–1153.
18. Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol, 2008, 26(24): 3950–3957.
19. Gluz O, Nitz U, et al. Comparison of Neoadjuvant Nab-Paclitaxel1Carboplatin vs Nab-Paclitaxel1Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. JNCI J Natl Cancer Inst, 2018, 110(6): djx258.
20. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol, 2005, 23(31): 7794-803.
21. Ciruelos E, Christian Jackisch. paclitaxel (Abraxane) in women with aggressive metastatic breast cancer Expert Rev. Anticancer Ther, 2014, 14(5): 511–521.
22. Bernardo A, Palumbo R, Pedersini R, et al. NabPaclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials. Clinical Breast Cancer, 2017 Oct, 17(6): 433-440.
23. Sun S, Tang L, Zhang J, et al. Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. International Journal of Nanomedicine, 2014, 9: 1443-1452.
24. Yardley DA, Coleman R, Conte P, et al. nabPaclitaxel Plus Carboplatin or Gemcitabine vs Gemcitabine Plus Carboplatin as First-Line Treatment for Patients With Triple-Negative Metastatic Breast Cancer: Results From the tnAcity Trial. Downloaded from https://academic.oup.com/annonc/advance-article-abstract/ doi/10.1093/annonc/mdy201/5033593.
25. Barton VN, Gordon MA, Richer JK, Elias A. Antiandrogen therapy in triple-negative breast cancer. Therapeutic Advances in Medical Oncology, 2016, 8(4): 305-308.
26. Robson M, Seock-Ah Im, Senkus E. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med, 2017, 377: 523-533.
Review
For citations:
Zhukova LG, Bardovskaya KS, Lubennikova EV, Suslova IR. The prospects for cisplatin and nab-paclitaxel combination therapy in patients with pre-treated triple-negative breast cancer. Description of the clinical case. Meditsinskiy sovet = Medical Council. 2018;(10):49-55. (In Russ.) https://doi.org/10.21518/2079-701X-2018-10-49-55
Views:
922
Email this article 